BRPI0510808A - derivados de benzonitrila para tratar fragilidade musculoesquelética - Google Patents

derivados de benzonitrila para tratar fragilidade musculoesquelética

Info

Publication number
BRPI0510808A
BRPI0510808A BRPI0510808-0A BRPI0510808A BRPI0510808A BR PI0510808 A BRPI0510808 A BR PI0510808A BR PI0510808 A BRPI0510808 A BR PI0510808A BR PI0510808 A BRPI0510808 A BR PI0510808A
Authority
BR
Brazil
Prior art keywords
treat
derivatives
mass
benzonitrile derivatives
substituted benzonitrile
Prior art date
Application number
BRPI0510808-0A
Other languages
English (en)
Inventor
Thomas George Gant
Roger James Hill
Hua Zhu Ke
Bruce Allen Lefker
James Paul O'malley
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0510808A publication Critical patent/BRPI0510808A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

DERIVADOS DE BENZONITRILA PARA TRATAR FRAGILIDADE MUSCULOESQUELéTICA. A presente invenção refere-se a novos derivados de benzonitrila substituída por amina e a composições farmacêuticas contendo os novos derivados de benzonitrila substituída por amina. A presente invenção também refere-se a métodos de tratamento usando derivados de benzonitrila substituída por amino para prevenir e/ou restaurar o declínio relacionado a idade na massa muscular e na resistência, tratar uma doença de desgaste, tratar uma condição que previne de baixa massa óssea, aumentar massa muscular, aumentar massa corporal magra, diminuir massa corporal gorda, e tratar fratura de osso e lesão muscular em mamíferos, incluindo seres humanos.
BRPI0510808-0A 2004-05-11 2005-04-29 derivados de benzonitrila para tratar fragilidade musculoesquelética BRPI0510808A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56987404P 2004-05-11 2004-05-11
US65844805P 2005-03-03 2005-03-03
PCT/IB2005/001250 WO2005108351A1 (en) 2004-05-11 2005-04-29 Benzonitrile derivatives to treat musculoskeletal frailty

Publications (1)

Publication Number Publication Date
BRPI0510808A true BRPI0510808A (pt) 2007-11-06

Family

ID=34967090

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510808-0A BRPI0510808A (pt) 2004-05-11 2005-04-29 derivados de benzonitrila para tratar fragilidade musculoesquelética

Country Status (7)

Country Link
US (1) US20080045504A1 (pt)
EP (1) EP1747193A1 (pt)
JP (1) JP2007537236A (pt)
BR (1) BRPI0510808A (pt)
CA (1) CA2565544A1 (pt)
MX (1) MXPA06013115A (pt)
WO (1) WO2005108351A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592452B2 (en) 2005-08-01 2013-11-26 Takeda Pharmaceutical Company Limited Cyclic amine compound
CA2670976C (en) 2006-11-30 2015-01-27 Atsushi Hasuoka Cyclic amine compound
ES2406685T3 (es) 2007-08-07 2013-06-07 Takeda Pharmaceutical Company Limited Derivados de pirrolidin-2-ona como moduladores de los receptores de andrógenos
JP2009084254A (ja) * 2007-10-03 2009-04-23 Sumitomo Chemical Co Ltd アミロイドβタンパク質の蓄積を抑制するための医薬組成物
DK2222636T3 (da) 2007-12-21 2013-06-03 Ligand Pharm Inc Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
WO2011143469A1 (en) 2010-05-12 2011-11-17 Radius Health,Inc Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
TW201534586A (zh) 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
DK3122426T3 (da) 2014-03-28 2023-04-03 Univ Duke Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
MX2017013802A (es) 2015-04-29 2018-08-15 Radius Pharmaceuticals Inc Métodos para tratar el cáncer.
EP4066827A1 (en) 2016-06-22 2022-10-05 Ellipses Pharma Ltd Ar+ breast cancer treatment methods
MX2019007748A (es) 2017-01-05 2019-09-09 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
JP2022532342A (ja) 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator
JP2022040051A (ja) 2020-08-27 2022-03-10 ユニテックフーズ株式会社 筋損傷回復促進用組成物
MX2023011241A (es) 2021-03-23 2023-10-03 Nuvation Bio Inc Compuestos dirigidos a receptores de hormonas nucleares contra el cancer.
EP4334314A1 (en) 2021-05-03 2024-03-13 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1122242B1 (en) * 1998-09-22 2008-01-16 Astellas Pharma Inc. Cyanophenyl derivatives
JP4160715B2 (ja) * 2000-06-15 2008-10-08 太陽誘電株式会社 光情報記録媒体
ES2321933T3 (es) * 2000-08-24 2009-06-15 University Of Tennessee Research Foundation Moduladores selectivos del receptor de androgeno y metodos de uso de los mismos.
WO2005000795A2 (en) * 2003-06-10 2005-01-06 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
GB0324551D0 (en) * 2003-10-21 2003-11-26 Karobio Ab Novel compounds

Also Published As

Publication number Publication date
CA2565544A1 (en) 2005-11-17
EP1747193A1 (en) 2007-01-31
MXPA06013115A (es) 2007-02-28
US20080045504A1 (en) 2008-02-21
JP2007537236A (ja) 2007-12-20
WO2005108351A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
BRPI0510808A (pt) derivados de benzonitrila para tratar fragilidade musculoesquelética
BR0309855A (pt) Pirazolpiridinas substituìdas com carbamato
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BRPI0510074A (pt) composições farmacêuticas para o tratamento de distúrbios sexuais ii
BR112012015961A2 (pt) composições incluindo piruvato para animais de estimação e métodos de uso dos mesmos
BR112013000446A2 (pt) composição nutricional para a estimulação de síntese de proteína muscular
BRPI0510430A (pt) composições e métodos para vacinação mucosal
MY147489A (en) Methods for the treatment of muscle loss
DE602005016601D1 (de) 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
EA200800157A1 (ru) Антагонисты npy, способ их получения и применение
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
UY28376A1 (es) Agentes terapéuticos
BR112012012811A2 (pt) metodo de intensificar a sintese de proteina no musculo
CO2020004801A2 (es) Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares
BR0307410A (pt) Uso de inibidores de pde5 no tratamento da cicatrização e fibrose
EA201400423A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BRPI0923783A8 (pt) Métodos para induzir perda de gordura corporal, e para aumentar a percentagem de massa de músculo magro em um animal de estimação
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BRPI0411347A (pt) combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia
GT199900083A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica.
DE60321175D1 (de) Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A E 6 ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.